Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Shares Outstanding (Diluted Average): 2018-2024

Historic Shares Outstanding (Diluted Average) for Catalyst Pharmaceuticals (CPRX) over the last 6 years, with Mar 2024 value amounting to $123.4 million.

  • Catalyst Pharmaceuticals' Shares Outstanding (Diluted Average) rose 8.26% to $123.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $123.4 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of $113.8 million for FY2023, which is 2.13% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $123.4 million for Q1 2024, which was up 8.48% from $113.8 million recorded in Q4 2023.
  • Catalyst Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $123.4 million during Q1 2024, with a 5-year trough of $106.2 million in Q4 2020.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Shares Outstanding (Diluted Average) value was $113.8 million (recorded in 2023), while the average stood at $113.4 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first fell by 0.62% in 2020, then climbed by 8.26% in 2024.
  • Catalyst Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $106.2 million in 2020, then grew by 1.46% to $107.8 million in 2021, then grew by 3.32% to $111.4 million in 2022, then increased by 2.13% to $113.8 million in 2023, then climbed by 8.26% to $123.4 million in 2024.
  • Its last three reported values are $123.4 million in Q1 2024, $113.8 million for Q4 2023, and $113.8 million during Q3 2023.